X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The acquisition adds ELE-101, a next-generation, short-duration psychedelic ready for Phase 1 clinical trials, to Beckley Psytech’s pipeline. ELE-101 is an intravenous (IV) formulation of psilocin, the active metabolite of psilocybin.
Lead Product(s): Psilocin
Therapeutic Area: Psychiatry/Psychology Product Name: ELE-101
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Beckley Psytech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition October 24, 2022
Details:
Merger also to support nationwide expansion of Eleusis’s subsidiary Andala, which manages in-network drug therapy clinics targeting the “last mile” challenge of psychedelic care delivery to address a potential $7 billion U.S. health care services opportunity.
Lead Product(s): ELE-Psilo
Therapeutic Area: Psychiatry/Psychology Product Name: ELE-Psilo
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Silver Spike Acquisition Corp
Deal Size: $446.0 million Upfront Cash: Undisclosed
Deal Type: Merger January 20, 2022
Details:
ELE-Ket+ and ELE-Psilo+ are expected to enter Phase II clinical trials for the adjunctive treatment of major depressive disorder at the end of 2021. Under the terms of the agreement, Eleusis will acquire Kalypso and its intellectual property in an all-stock transaction.
Lead Product(s): ELE-Psilo+
Therapeutic Area: Psychiatry/Psychology Product Name: ELE-Psilo+
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Kalypso Wellness Centers
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition December 14, 2020
Details:
The research reveals that both psilocybin and lysergic acid diethylamide (LSD) significantly reduce depressive-like behaviors five weeks after a single administration.
Lead Product(s): Psilocybine,LSD
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 05, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
